BioSpace News Archive

Researchers Hope Giving Remdesivir Along with a Powerful Anti-Inflammatory Could be the Key to Treating the Most Severe COVID-19 Cases

The Myositis Association (TMA) is excited to announce that recipients of the TMA’s Innovative Research Grant, Professor Ian Hampson, Dr. Janine Lamb, and Dr. Spyridon Megremis at the University of Manchester have developed a novel approach to identify the targets of antibodies produced by the immune system in myositis patients.

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its Prospera donor-derived cell-free DNA (dd-cfDNA) transplant assessment test at the 2020 American

and nearly a quarter of those hospitalized died or were discharged to hospice, including 60 percent who required ventilators.

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing therapeutic cell-engineering technologies, today announced that the United States Patent and Trademark Office has granted Factor Bioscience U.S. Patent No. 10,662,410 covering methods for producing a gene-edited cell using mRNA encoding transcription activator-like effector nucleases (TALENs)

BioDuro, LLC, a leading drug discovery and development services organization, announced today the availability of two new preclinical models for Non-alcoholic steatohepatitis (NASH) that highly resemble clinical progression of the disease and do so in a matter of 2-3 months.

Digirad Corporation, a diversified holding company with three operating divisions: healthcare, building and construction, and real estate and investments, announced the pricing of an underwritten public offering of 2,225,000 shares of its common stock and warrants to purchase up to 1,112,500 shares of the Company’s common stock.

MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics, is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors.

Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the peer-reviewed publication of methods used to evaluate the on-target efficiency and precision of Homology’s in vivo phenylketonuria (PKU) gene editing program.

The Institute of Cancer Research, London, has strongly welcomed the approval by the US Food and Drug Administration (FDA) of the genetically targeted drug olaparib for some men with advanced prostate cancer.